"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 9 | 9 |
| 2005 | 0 | 11 | 11 |
| 2006 | 0 | 13 | 13 |
| 2007 | 0 | 15 | 15 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 9 | 9 |
| 2010 | 0 | 13 | 13 |
| 2011 | 0 | 11 | 11 |
| 2012 | 0 | 8 | 8 |
| 2013 | 0 | 8 | 8 |
| 2014 | 0 | 15 | 15 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 10 | 10 |
| 2017 | 0 | 6 | 6 |
| 2018 | 0 | 9 | 9 |
| 2019 | 0 | 7 | 7 |
| 2020 | 0 | 5 | 5 |
| 2021 | 0 | 6 | 6 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 2 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Unravelling the anti-cancer mechanisms elicited by non-covalent thioredoxin reductase inhibitors for triple negative breast cancer therapy. Redox Biol. 2026 03; 90:103980.
-
Pleiotropic anti-cancer activities of novel non-covalent thioredoxin reductase inhibitors against triple negative breast cancer. Free Radic Biol Med. 2025 02 01; 227:201-209.
-
Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. J Biol Chem. 2024 Jun; 300(6):107375.
-
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer. J Immunother Cancer. 2023 07; 11(7).
-
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines. Int J Mol Sci. 2023 Apr 27; 24(9).
-
Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles. Proc Natl Acad Sci U S A. 2022 09 20; 119(38):e2205454119.
-
Commentary: Tumor biology remains the star of the show. J Thorac Cardiovasc Surg. 2023 03; 165(3):898-899.
-
RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.
-
Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. Mol Neurobiol. 2022 Feb; 59(2):1262-1272.
-
Xenogeneic fibroblasts inhibit the growth of the breast and ovarian cancer cell lines in co-culture. Neoplasma. 2021 Nov; 68(6):1265-1271.